Milestone Pharmaceuticals Inc. filings document a commercial-stage biopharmaceutical company focused on cardiovascular medicines, including CARDAMYST (etripamil) nasal spray for adults with PSVT. Its 8-K filings report financial results, commercial launch updates, regulatory and corporate updates, Regulation FD presentations and material events related to etripamil.
The filing record also covers Milestone's Nasdaq-listed common shares, proxy governance for annual shareholder meetings, board and voting matters, and capital-structure items such as the completed sale of a royalty interest tied to U.S. etripamil net product sales. These disclosures provide formal records of operating results, governance, financing arrangements and product-related corporate events.
Milestone Pharmaceuticals Inc. is asking shareholders to vote at a virtual-only 2026 Annual Meeting on June 10, 2026 at 11:00 a.m. Eastern Time. Shareholders of record as of April 15, 2026, when 119,637,391 common shares were outstanding, may vote online, by phone or by mail.
Investors will elect eight directors, ratify PricewaterhouseCoopers LLP as auditor through the 2027 meeting, approve an increase of 6,800,000 shares under the 2019 Equity Incentive Plan, and cast a non-binding advisory vote on executive compensation. The Board, led by an independent chair, recommends voting FOR all proposals and highlights strong governance practices, including a majority-independent board, fully independent key committees and no shareholder rights plan.
Milestone Pharmaceuticals President and CEO Joseph Oliveto sold 36,500 common shares of the company in an open-market transaction on April 16, 2026 at a weighted average price of $2.26 per share. The shares were sold in multiple trades between $2.25 and $2.28 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan previously adopted by Oliveto, meaning the trades were pre-scheduled rather than discretionary. Following this transaction, he continues to hold 446,244 common shares directly.
Milestone Pharmaceuticals Inc. reports amended Schedule 13G disclosures identifying beneficial ownership by Trails Edge-related filers. The filing states that, as of March 20, 2026, each Filer may be deemed to beneficially own 5,333,333 shares underlying Series B warrants, representing 4.3% of the issued and outstanding shares reported as 117,667,277 in the company's Form 10-K. The disclosure clarifies voting and dispositive power is held solely by the Filers and is filed jointly under a previously executed joint filing agreement.
Milestone Pharmaceuticals Inc. filed an initial ownership report for its GC & Chief Compliance Officer, David I. Sandoval. He holds an employee stock option to buy 400,000 common shares at an exercise price of $1.9600 per share, expiring on January 19, 2036. One-fourth of the option vests on January 19, 2027, with the remaining shares vesting monthly over the following 36 months, subject to continued service.
Milestone Pharmaceuticals reported a larger net loss in 2025 as it transitioned into commercial stage following FDA approval of CARDAMYST nasal spray for paroxysmal supraventricular tachycardia (PSVT) and its U.S. launch. Revenue reached $1,546 thousand in 2025, up from none in 2024, reflecting initial product and license activity.
Operating expenses rose as the company invested in research, administration and a full commercial build-out, leading to a net loss of $63,058 thousand versus $41,519 thousand in 2024, or a basic and diluted net loss per share of $0.75 compared with $0.67. Year-end 2025 cash and cash equivalents were $73,046 thousand, with total assets of $113,561 thousand and shareholders’ equity of $41,769 thousand.
Milestone Pharmaceuticals filed its annual report outlining a pivotal year in which the FDA approved CARDAMYST (etripamil) nasal spray for at-home treatment of PSVT and U.S. commercialization began in early 2026. The company is pursuing additional approvals, including an application filed with the EMA and an NDA accepted in China via partner Corxel.
Milestone is also advancing etripamil for atrial fibrillation with rapid ventricular rate, supported by positive Phase 2 ReVeRA data and an agreed Phase 3/sNDA path with the FDA. Despite this progress, the company remains loss-making, with a 2025 net loss of $63.1 million and an accumulated deficit of $430.6 million, and expects continued substantial operating losses while it invests in commercialization and late-stage development.
Milestone Pharmaceuticals President and CEO Joseph Oliveto filed an amended insider report updating the terms of a previously disclosed stock option grant. The filing shows an employee stock option to purchase 679,000 common shares at an exercise price of $1.96 per share.
The amendment states that the exercise price on the initial filings was incorrectly stated and is now corrected. One-fourth of the option shares will vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting each month afterward, as long as Oliveto continues to provide service.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Medical Officer. The officer received an employee stock option to buy 204,000 common shares at an exercise price of $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036.
The amendment corrects an initially misstated exercise price. One-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing services.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Operating Officer. The filing corrects the exercise price on previously reported employee stock options and confirms a grant of 204,000 options with an exercise price of $1.96 per common share.
The options expire on February 2, 2036. One-fourth of the shares underlying the option vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, as long as the executive continues providing service through each vesting date.